VYNE Finalizes $17.3M Special Dividend and 1-for-50 Reverse Split Ahead of Yarrow Merger
VYNE has more than doubled off its 52-week low of $0.281 on elevated volume (3.8× avg).
Summary
VYNE Therapeutics announced a $17.3 million special cash dividend and a 1-for-50 reverse stock split as final steps before its reverse merger with Yarrow Bioscience closes, with the combined company expected to begin trading on July 27.
Key Events · Financing and Capital Events · VYNE
-
Special Cash Dividend Finalized
An aggregate cash dividend of $17.3 million, or approximately $0.40242 per share, will be paid to stockholders and warrant holders of record as of July 22, 2026, with payment expected on July 23, 2026.
-
1-for-50 Reverse Stock Split Approved
The board approved a 1-for-50 reverse stock split, reducing outstanding shares from roughly 33.4 million to about 0.7 million, effective before the merger closes.
-
Post-Merger Share Structure Disclosed
After the reverse split and merger, the combined company is expected to have roughly 2.7 million shares outstanding, about 33.6 million fully diluted, or approximately 28.6 million excluding equity plans.
-
Merger Closing Timeline Confirmed
The merger with Yarrow Bioscience is expected to close on or about July 24, 2026, with the combined company trading as YARW on Nasdaq starting July 27, 2026.
Analysis · VYNE · Life Sciences
VYNE Therapeutics is locking in the final terms of its reverse merger with Yarrow Bioscience. The board approved a 1-for-50 reverse stock split, which will shrink outstanding shares from roughly 33.4 million to about 0.7 million. More critically, the company declared a $17.3 million special cash dividend—approximately $0.40242 per share—payable to holders of record as of July 22, 2026. This distribution is a key condition of the merger and represents a significant return of capital to existing shareholders before the combined entity begins trading as Yarrow Bioscience (YARW) on July 27. The filing also clarifies the post-merger share structure: roughly 2.7 million shares outstanding, or about 33.6 million fully diluted. For a micro-cap company with a market cap around $35 million, a $17.3 million cash distribution is a major corporate event that directly impacts shareholder value and signals the merger is on track to close imminently.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VYNE was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.7M. The 52-week trading range was $0.28 to $1.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.